SCHEMBL6079954

SCHEMBL6079954

Cc1c(C(=O)O)nc2c(O)ccc(-c3ccccc3)c2c1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 2/20 0.39
RNASEH1 O60930 1/20 0.38
ERCC1 P07992 1/20 0.38
FEN1 P39748 1/20 0.38
ERCC4 Q92889 1/20 0.38
HNF4A P41235 1/20 0.36
CYP1A2 P05177 2/20 0.35
PTPN1 P18031 1/20 0.35
TSHR P16473 1/20 0.35
PDE10A Q9Y233 1/20 0.35
MCL1 Q07820 1/20 0.35
CA12 O43570 1/20 0.35
TNF P01375 1/20 0.35
CA9 Q16790 1/20 0.35
NOD2 Q9HC29 1/20 0.35
NOD1 Q9Y239 1/20 0.35
KDM6B O15054 1/20 0.34
FTO Q9C0B1 1/20 0.34
EGLN1 Q9GZT9 1/20 0.34
KDM4C Q9H3R0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080473 0.86 PIN1 (0.38) PIN1RNASEH1ERCC1FEN1ERCC4
SCHEMBL6081286 0.80 CYP2C9 (0.46) MCL1DHODHMAPTSMN1; SMN2CYP2C19
SCHEMBL6080976 0.79 MEN1 (0.36) RNASEH1KDM6BFTOEGLN1KDM4C
SCHEMBL6080809 0.78 EPRS1 (0.36) RNASEH1CYP1A2DHODHMAPTCYP2C19
SCHEMBL6080782 0.76 DHODH (0.50) PIN1RNASEH1ERCC1FEN1ERCC4
SCHEMBL6080250 0.74 DHODH (0.41) CYP1A2TSHRDHODHALDH1A1MAPT
SCHEMBL6080071 0.72 KDM4E (0.44) HNF4APTPN1MCL1KDM4CALDH1A1
SCHEMBL6080384 0.72 KDM4E (0.46) CYP1A2PDE10ACA12CA9KDM6B
SCHEMBL6078796 0.68 MAPT (0.41) PIN1RNASEH1TSHRDHODHALDH1A1
SCHEMBL6079878 0.68 EGFR (0.49) ERCC1FEN1ERCC4ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL PIN1 3446/4885RNASEH1 2268/4885ERCC1 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.